Zobrazeno 1 - 10
of 179
pro vyhledávání: '"Sebastian Mirkin"'
Autor:
Jennifer J. Virro, Kathleen Besinque, Christiane E. Carney, Danielle Gross, Brian Bernick, Sebastian Mirkin
Publikováno v:
Pharmacy, Vol 8, Iss 3, p 156 (2020)
Annovera (segesterone acetate and ethinyl estradiol vaginal system) is a US Food and Drug Administration FDA-approved long-lasting, reversible contraceptive that is fully administered by the user and does not require a procedure for insertion or remo
Externí odkaz:
https://doaj.org/article/d4ce23ddde6f4d718ead41d99dfbc30a
Autor:
Sebastian Mirkin, Barry S. Komm
Publikováno v:
Pharmaceuticals, Vol 5, Iss 9, Pp 899-924 (2012)
Menopause is associated with health concerns including vasomotor symptoms, vulvar/vaginal atrophy (VVA), and osteoporosis. Estrogen therapy or combined estrogen-progestin therapy (EPT) are primary treatment options for menopausal symptom relief and o
Externí odkaz:
https://doaj.org/article/a1a9e9bcd8384a9faef30d26c7bb1cd0
Autor:
Michael R, McClung, Risa, Kagan, Shelli, Graham, Brian, Bernick, Sebastian, Mirkin, Ginger, Constantine
Publikováno v:
Menopause. 29:304-308
To evaluate bone turnover markers (BTM) in the REPLENISH trial (NCT01942668).REPLENISH evaluated oral estradiol/progesterone (E2/P4) for the treatment of moderate to severe vasomotor symptoms (VMS) in postmenopausal women with a uterus. Eligible wome
Autor:
Sebastian Mirkin, James H. Liu, Barry S. Komm, David F. Archer, Shelli Graham, Brian Bernick, Patricia Castro, James A. Simon
Publikováno v:
Menopause (New York, N.y.)
Objective: To evaluate endometrial progesterone receptor (PGR) expression in menopausal women who used vaginal 4-μg and 10-μg estradiol (E2) inserts or placebo. Methods: REJOICE was a randomized, placebo-controlled trial investigating vaginal E2 in
Publikováno v:
Expert Opinion on Drug Delivery. 17:1573-1581
Introduction Vulvar and vaginal atrophy (VVA) affects up to two thirds of postmenopausal women, with symptoms of vaginal dryness, dyspareunia, and vulvar/vaginal irritation. Despite the availability of various treatments, women express dissatisfactio
Autor:
Sebastian Mirkin, David F. Archer, A. Shah, Brian Bernick, Terry A. Jacot, Intira Sriprasert, Tarita Pakrashi
Publikováno v:
Climacteric. 23:306-310
Objective: We compared cervico-vaginal cytokines in hormone therapy (HT)-treated postmenopausal women with premenopausal women and explored the association of serum estradiol (E2) and progesterone ...
Publikováno v:
Climacteric
OBJECTIVE: This study evaluated associations of estradiol (E2) dose and serum E2 levels with coagulation/anti-coagulation measures in early (
Autor:
James A. Simon, Sebastian Mirkin, Shelli Graham, James H. Pickar, Bharat Warrier, Annette M. Shadiack, Brian Bernick
Publikováno v:
Menopause (New York, N.y.)
Objective: TX-004HR is a low-dose estradiol (E2) softgel vaginal insert designed to be rapidly dissolving and mucoadhesive. This report describes the physical attributes and pharmacokinetic parameters of the softgel vaginal insert evaluated for the t
Publikováno v:
Menopause. 26:966-971
To analytically characterize the doses of estradiol and progesterone found in compounded combined forms of oral capsule and transdermal cream formulations, and determine the consistency of the hormone formulations within a batch.Prescriptions for com
Autor:
Roger A. Lobo, B. Bernick, Nanette Santoro, Sebastian Mirkin, Shelli Graham, Andrew M. Kaunitz
Publikováno v:
Climacteric. 22:610-616
Objective: This study aimed to evaluate the effects of TX-001HR (17β-estradiol [E2] and progesterone [P4] in a single oral capsule) on cardiometabolic markers and outcomes.Methods: Four E2/P4 doses...